Table 1.
Characteristics of the included studies in this meta-analysis
| Reference | Year | Country | Disease type | Patients (n) | Male/female | Included years | Age (years)* | Prognostic index | Detection method | Cut-off value | Survival type (analysis type) |
Follow-up | Treatments | Stage |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hwang et al10 | 2017 | Korea | BC | 793 | 0/793 | 2000–2016 | 54.1±12.3 | FAR | ROC curve | 7.1 | OS (M) | ≥5 years | With-surgery | I-II-III |
| Tan et al11 | 2017 | China | ESCC | 1135 | 888/247 | 2008–2010 | 58 (28–88) | FAR | X-tile software | 0.08 | OS (M) | ≥5 years | With-surgery | NA |
| Zhang et al12 | 2017 | China | GC | 360 | 261/99 | 2011–2013 | 58.24±11.22 | AFR | X-tile software | 8.9 | OS (M) | <5 years | With-surgery | II -III |
| Xu et al16 | 2018 | China | HCC | 151 | 128/23 | 2006–2010 | 51 (22–78) | FAR | ROC curve | 0.062 | OS (M) | ≥5 years | With-surgery | BCLC (0-A-B-C) |
| Chen et al17 | 2018 | China | NSCLC | 529 | 312/217 | 2010–2015 | 62 (28–82) | AFR | ROC curve | 9.67 | OS (M), DFS (M) | ≥5 years | With-surgery | I-II-III |
| Li et al18 | 2018 | China | NSCLC | 412 | 317/95 | 2005–2014 | 60.33±8.97 | AFR | X-tile software | 7.8 | OS (M) | <5 years | Mixed | I-II-III-IV |
| Sun et al13 | 2018 | China | CRC | 680 | 426/254 | 2008–2013 | NA | AFR | X-tile software | 9.2 | OS (M) | <5 years | With-surgery | I-II-III |
| Xu et al19 | 2018 | China | GBC | 154 | 63/91 | 2005–2017 | 64 (29–85) | FAR | ROC curve | 0.08 | OS (M) | ≥5 years | With-surgery | I-II-III-IV |
| Zou et al20 | 2018 | China | CLL | 191 | 128/63 | 1995–2017 | 61 (23–86) | AFR | X-tile software | 9.7 | OS (M) | ≥5 years | Untreated | Binet A-B-C stage |
| Liang et al21 | 2018 | China | STS | 310 | 174/136 | 1999–2013 | 39 (5–78) | FAR | ROC curve | 0.0726 | OS (M), DFS (U) | ≥5 years | With-surgery | I-II-III-IV |
| Gao et al22 | 2018 | China | ESCC | 153 | 128/25 | 2011–2013 | 61.93±6.72 | AFR | X-tile software | 9.3 | OS (M) | <5 years | With-surgery | 0-I-II-III |
| Du et al 23 | 2018 | China | GBC | 220 | 122/98 | 2009–2015 | NA | AFR | X-tile software | 15.45 | OS (M) | <5 years | Mixed | Metastatic |
Note: *Data shown as median (interquartile range) or mean ± standard deviation.
Abbreviations: BC, breast cancer; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; HCC, hepatocellular carcinoma; NSCLC, non-small cell lung cancer; CRC, colorectal cancer; GBC, gallbladder cancer; CLL, chronic lymphocytic leukemia; STS, soft tissue sarcoma; OS, overall survival; DFS, disease-free survival; AFR, albumin/fibrinogen ratio; FAR, fibrinogen/albumin ratio; ROC, receiver operating characteristic; M, multivariate analysis, U, univariate analysis, NA, not available.